Very interesting deal
“, expects to start its first human clinical trial within a year in frontotemporal dementia, .....
Four other Alector drugs could follow into the clinic over the next two years”
This shows that if BP thinks a drug or approach has potential and they can trust management, they will enter into partnership.
Despite touting A2-73 potential in ALZ and other CNS, AVXL did not have any deals - does it tell that BP do not have confidence in A2-73?
News 
Market Data 
Discover 
